Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
12.07B
Market cap12.07B
Price-Earnings ratio
-42.81
Price-Earnings ratio-42.81
Dividend yield
Dividend yield
Average volume
3.89M
Average volume3.89M
High today
$74.52
High today$74.52
Low today
$71.99
Low today$71.99
Open price
$72.81
Open price$72.81
Volume
2.02M
Volume2.02M
52 Week high
$76.78
52 Week high$76.78
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $74.50. The company's market cap stands at 12.07B, with a P/E ratio of -42.81.

On 2025-11-18, Ionis Pharmaceuticals(IONS) stock moved within a range of $71.99 to $74.52. With shares now at $74.50, the stock is trading +3.5% above its intraday low and -0.0% below the session's peak.

Trading activity shows a volume of 2.02M, compared to an average daily volume of 3.89M.

The stock's 52-week range extends from a low of $23.95 to a high of $76.78.

The stock's 52-week range extends from a low of $23.95 to a high of $76.78.

IONS News

TipRanks 4d
Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has ad...

Simply Wall St 5d
Ionis Pharmaceuticals Rallies on Positive Phase 3 Olezarsen Data Could Approval Transform Its Growth Story?

Ionis Pharmaceuticals recently announced positive results from its pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia, with the...

Ionis Pharmaceuticals Rallies on Positive Phase 3 Olezarsen Data Could Approval Transform Its Growth Story?
Investing.com 5d
Ionis Pharmaceuticals at Stifel Conference: Strategic Growth Insights - Investing.com

...

Ionis Pharmaceuticals at Stifel Conference: Strategic Growth Insights - Investing.com

Analyst ratings

71%

of 24 ratings
Buy
70.8%
Hold
29.2%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.